Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Umecrine Cognition AB
AB
Active
Org 5566983655
Nanna Svartz Väg 6 A, 171 65
Solna
Manufacture of pharmaceutical preparations
·
NACE 2120
Est. 2006 · 20 years old
1-4 employees
Monitor
Share
Sweden
/
Companies
/
Manufacture of pharmaceutical preparations
/
Umecrine Cognition AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2021: 0M
0M
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
2025: 0M
0M
2025
EBITDA
SEK millions
0M
-20M
-40M
-61M
-81M
2021: -16M
-16M
2021
2022: -46M (-187% vs 2021)
-46M
-187%
2022
2023: -40M (+13% vs 2022)
-40M
+13%
2023
2024: -65M (-62% vs 2023)
-65M
-62%
2024
2025: -14M (+78% vs 2024)
-14M
+78%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
0
0
0
0
7
Staff expenses
−9 524
—
—
—
—
EBITDA
−13 753
−64 613
−40 095
−46 207
−16 475
Depreciation & amort.
−0
−0
−47
−57
−41
EBIT
−50 675
−64 613
−40 142
−46 264
−16 516
Net financials
−6 015
−6 138
−2 845
−622
−9 896
Profit before tax
−56 690
−70 751
−42 986
−46 886
−26 413
Tax
−0
−0
−0
−0
−0
Net profit
−56 690
−70 751
−42 986
−46 886
−26 413
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
130 305
131 082
143 006
119 569
74 874
Equity
113 273
−48 779
21 972
64 958
61 844
Long-term debt
0
10 581
113 437
51 346
10 581
Short-term debt
17 032
169 280
7 598
3 265
2 449
Total debt
17 032
179 861
121 035
54 611
13 030
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2021
2025
Equity ratio
86,9 %
This company
38,2 %
Market median
This company
Market median
127% above market
2021
2025
Return on equity
−50,0 %
This company
18,4 %
Market median
This company
Market median
372% below market
2021
2025
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2021
2025
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2021
2025
Debt / equity
0,15×
This company
0,62×
Market median
This company
Market median
76% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-05-01 – 2021-12-31
View
PDF
More on Umecrine Cognition AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
